Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations

Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature reviews. Neurology Ročník 16; číslo 3; s. 154 - 170
Hlavní autoři: Mao-Draayer, Yang, Thiel, Sandra, Mills, Elizabeth A, Chitnis, Tanuja, Fabian, Michelle, Katz Sand, Ilana, Leite, M Isabel, Jarius, Sven, Hellwig, Kerstin
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Nature Publishing Group 01.03.2020
Témata:
ISSN:1759-4758, 1759-4766, 1759-4766
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearing age. Although NMOSD are rare, several small retrospective studies and case reports have indicated that pregnancy can worsen disease activity and might contribute to disease onset. NMOSD disease activity seems to negatively affect pregnancy outcomes. Moreover, some of the current NMOSD treatments are known to pose risks to the developing fetus and only limited safety data are available for others. Here, we review published studies regarding the relationship between pregnancy outcomes and NMOSD disease activity. We also assess the risks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and breastfeeding. On the basis of the available evidence, we offer recommendations regarding the use of these therapies in the course of pregnancy planning in individuals with NMOSD.
AbstractList Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearing age. Although NMOSD are rare, several small retrospective studies and case reports have indicated that pregnancy can worsen disease activity and might contribute to disease onset. NMOSD disease activity seems to negatively affect pregnancy outcomes. Moreover, some of the current NMOSD treatments are known to pose risks to the developing fetus and only limited safety data are available for others. Here, we review published studies regarding the relationship between pregnancy outcomes and NMOSD disease activity. We also assess the risks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and breastfeeding. On the basis of the available evidence, we offer recommendations regarding the use of these therapies in the course of pregnancy planning in individuals with NMOSD.Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation. In this Review, the authors discuss the relationship between pregnancy outcomes and NMOSD disease activity, and outline potential treatment approaches.
Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearing age. Although NMOSD are rare, several small retrospective studies and case reports have indicated that pregnancy can worsen disease activity and might contribute to disease onset. NMOSD disease activity seems to negatively affect pregnancy outcomes. Moreover, some of the current NMOSD treatments are known to pose risks to the developing fetus and only limited safety data are available for others. Here, we review published studies regarding the relationship between pregnancy outcomes and NMOSD disease activity. We also assess the risks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and breastfeeding. On the basis of the available evidence, we offer recommendations regarding the use of these therapies in the course of pregnancy planning in individuals with NMOSD.
Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearing age. Although NMOSD are rare, several small retrospective studies and case reports have indicated that pregnancy can worsen disease activity and might contribute to disease onset. NMOSD disease activity seems to negatively affect pregnancy outcomes. Moreover, some of the current NMOSD treatments are known to pose risks to the developing fetus and only limited safety data are available for others. Here, we review published studies regarding the relationship between pregnancy outcomes and NMOSD disease activity. We also assess the risks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and breastfeeding. On the basis of the available evidence, we offer recommendations regarding the use of these therapies in the course of pregnancy planning in individuals with NMOSD.Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearing age. Although NMOSD are rare, several small retrospective studies and case reports have indicated that pregnancy can worsen disease activity and might contribute to disease onset. NMOSD disease activity seems to negatively affect pregnancy outcomes. Moreover, some of the current NMOSD treatments are known to pose risks to the developing fetus and only limited safety data are available for others. Here, we review published studies regarding the relationship between pregnancy outcomes and NMOSD disease activity. We also assess the risks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and breastfeeding. On the basis of the available evidence, we offer recommendations regarding the use of these therapies in the course of pregnancy planning in individuals with NMOSD.
Author Jarius, Sven
Mao-Draayer, Yang
Leite, M Isabel
Thiel, Sandra
Chitnis, Tanuja
Mills, Elizabeth A
Fabian, Michelle
Katz Sand, Ilana
Hellwig, Kerstin
Author_xml – sequence: 1
  givenname: Yang
  surname: Mao-Draayer
  fullname: Mao-Draayer, Yang
  organization: Graduate Program in Immunology, Program in Biomedical Sciences, University of Michigan Medical School, Ann Arbor, MI, USA
– sequence: 2
  givenname: Sandra
  surname: Thiel
  fullname: Thiel, Sandra
  organization: Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
– sequence: 3
  givenname: Elizabeth A
  surname: Mills
  fullname: Mills, Elizabeth A
  organization: Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA
– sequence: 4
  givenname: Tanuja
  orcidid: 0000-0002-9897-4422
  surname: Chitnis
  fullname: Chitnis, Tanuja
  organization: Department of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, MA, USA
– sequence: 5
  givenname: Michelle
  surname: Fabian
  fullname: Fabian, Michelle
  organization: Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
– sequence: 6
  givenname: Ilana
  surname: Katz Sand
  fullname: Katz Sand, Ilana
  organization: Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
– sequence: 7
  givenname: M Isabel
  surname: Leite
  fullname: Leite, M Isabel
  organization: Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
– sequence: 8
  givenname: Sven
  surname: Jarius
  fullname: Jarius, Sven
  organization: Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany
– sequence: 9
  givenname: Kerstin
  orcidid: 0000-0003-4467-9011
  surname: Hellwig
  fullname: Hellwig, Kerstin
  email: k.hellwig@klinikum-bochum.de
  organization: Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. k.hellwig@klinikum-bochum.de
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32080393$$D View this record in MEDLINE/PubMed
BookMark eNp90LtOwzAUBmALFVFaeAAWFImFJeBjx3bMhipuUgVCgjnyLZCqcYKdDHl7jCgMDEznHz6d2wLNfOcdQieALwDT8jIWwEqSY4JzTIHm0x46BMFkXgjOZ7-ZlXO0iHGDMeeUwAGaU4JLTCU9RM-PbgxdO7ltMzQx6_qhMSqLvTNDGNvMNrEL1oWYKW-zPrg3r7yZrrLh3QXVuzHxzHQ-NgmpoUnpCO3Xahvd8a4u0evtzcvqPl8_3T2srte5YbwYcq5KTEqw3ICA0soaJDHSUq1JocACB8l1zSRoa7XmQhBLONeJ8BoUB7pE5999-9B9jC4OVdtE47Zb5V03xopQAVCwdH2iZ3_ophuDT9tVJL1KCE4k-1dRgQuWlvkae7pTo26drfrQtCpM1c9L6SevaHpC
CitedBy_id crossref_primary_10_1177_1756286420936166
crossref_primary_10_1016_j_autrev_2023_103499
crossref_primary_10_1177_13524585241310376
crossref_primary_10_1038_s41598_025_88624_x
crossref_primary_10_1056_NEJMra1904655
crossref_primary_10_1016_j_lfs_2020_118217
crossref_primary_10_2169_internalmedicine_5870_25
crossref_primary_10_1016_j_aopr_2022_100064
crossref_primary_10_1016_j_chroma_2024_464701
crossref_primary_10_1212_CON_0000000000001237
crossref_primary_10_3390_ijms22168638
crossref_primary_10_1016_j_msard_2023_104620
crossref_primary_10_1212_WNL_0000000000011744
crossref_primary_10_18553_jmcp_2022_28_12_a_s1
crossref_primary_10_1016_j_msard_2025_106568
crossref_primary_10_2217_imt_2020_0163
crossref_primary_10_1007_s00415_020_10235_5
crossref_primary_10_1016_j_clineuro_2022_107342
crossref_primary_10_1111_cen3_12809
crossref_primary_10_1016_j_msard_2021_103418
crossref_primary_10_1016_j_msard_2020_102428
crossref_primary_10_1111_cen3_12724
crossref_primary_10_1177_13524585251349125
crossref_primary_10_1007_s11940_021_00667_3
crossref_primary_10_1212_CON_0000000000001168
crossref_primary_10_1016_S1634_7072_22_47095_4
crossref_primary_10_1515_ijamh_2021_0084
crossref_primary_10_3390_brainsci12010069
crossref_primary_10_1097_WCO_0000000000000922
crossref_primary_10_3389_fneur_2020_544434
crossref_primary_10_1016_j_msard_2025_106456
crossref_primary_10_1177_13524585241283648
crossref_primary_10_1177_1756286420981352
crossref_primary_10_1016_j_ogc_2020_11_007
crossref_primary_10_3389_fimmu_2022_966766
crossref_primary_10_2147_IJWH_S485822
crossref_primary_10_1177_13524585221129472
crossref_primary_10_1002_acn3_51683
crossref_primary_10_1016_j_msard_2020_102729
crossref_primary_10_1186_s12974_021_02249_1
crossref_primary_10_1080_14737175_2025_2548947
crossref_primary_10_1007_s00415_022_11241_5
crossref_primary_10_1212_NXI_0000000000200124
crossref_primary_10_1016_j_ncl_2021_02_008
crossref_primary_10_1212_CON_0000000000001059
crossref_primary_10_1007_s00115_021_01106_z
crossref_primary_10_3389_fimmu_2021_800666
crossref_primary_10_1212_NXI_0000000000000913
crossref_primary_10_4103_neurol_india_Neurol_India_D_23_00647
crossref_primary_10_1016_j_msard_2022_104023
crossref_primary_10_1016_j_msard_2022_103494
crossref_primary_10_1016_j_msard_2021_103310
crossref_primary_10_1016_j_msard_2023_104760
crossref_primary_10_1177_13524585231151953
crossref_primary_10_1016_j_jneuroim_2025_578585
crossref_primary_10_1177_1756286420949808
crossref_primary_10_1159_000544813
crossref_primary_10_1177_13524585221130934
crossref_primary_10_1038_s41572_020_0214_9
crossref_primary_10_3389_fneur_2022_1048502
crossref_primary_10_7759_cureus_40260
crossref_primary_10_1001_jamanetworkopen_2022_25438
crossref_primary_10_3390_ijms23084154
crossref_primary_10_1007_s11940_021_00666_4
crossref_primary_10_1212_CON_0000000000001108
crossref_primary_10_1007_s00415_023_11910_z
crossref_primary_10_1111_cen3_12784
crossref_primary_10_1177_17562864211054956
ContentType Journal Article
Copyright 2020© Springer Nature Limited 2020
Springer Nature Limited 2020.
Copyright_xml – notice: 2020© Springer Nature Limited 2020
– notice: Springer Nature Limited 2020.
DBID CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/s41582-020-0313-y
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
ProQuest One Academic Middle East (New)
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1759-4766
EndPage 170
ExternalDocumentID 32080393
Genre Journal Article
Review
GroupedDBID ---
0R~
29M
39C
53G
70F
7X7
88E
8FI
8FJ
AARCD
AAWTL
AAWYQ
AAYZH
ABAWZ
ABFSG
ABJNI
ABLJU
ABUWG
ACGFS
ACSTC
ADBBV
AENEX
AEZWR
AFANA
AFHIU
AFKRA
AFSHS
AGAYW
AHBCP
AHMBA
AHOSX
AHSBF
AHWEU
AIBTJ
AIXLP
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALPWD
ARMCB
ATHPR
AXYYD
BENPR
BKKNO
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
DB5
EBS
ECM
EE.
EIF
EJD
EXGXG
F5P
FQGFK
FSGXE
FYUFA
HMCUK
HZ~
IAO
IGS
IHR
IHW
INH
INR
ITC
M1P
NFIDA
NNMJJ
NPM
ODYON
OVD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RNR
RNT
RNTTT
SHXYY
SIXXV
SNYQT
SOJ
TAOOD
TBHMF
TDRGL
TEORI
TSG
UKHRP
3V.
7XB
8FK
AGSTI
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c564t-6a80281d6c1718d9f192c9d3bb24a1d16196bf591bddbb6772d266bc9d6f1a613
IEDL.DBID 7X7
ISICitedReferencesCount 67
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000517918500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1759-4758
1759-4766
IngestDate Wed Oct 01 13:32:39 EDT 2025
Tue Oct 07 06:51:44 EDT 2025
Sat Nov 29 14:36:56 EST 2025
Mon Jul 21 05:31:53 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-6a80281d6c1718d9f192c9d3bb24a1d16196bf591bddbb6772d266bc9d6f1a613
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-4467-9011
0000-0002-9897-4422
PMID 32080393
PQID 2370455911
PQPubID 2041930
PageCount 17
ParticipantIDs proquest_miscellaneous_2371145758
proquest_journals_2476776295
proquest_journals_2370455911
pubmed_primary_32080393
PublicationCentury 2000
PublicationDate 2020-03-01
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: 2020-03-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Nature reviews. Neurology
PublicationTitleAlternate Nat Rev Neurol
PublicationYear 2020
Publisher Nature Publishing Group
Publisher_xml – name: Nature Publishing Group
SSID ssj0066321
Score 2.5263672
SecondaryResourceType review_article
Snippet Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 154
SubjectTerms Abnormalities, Drug-Induced
Abortion, Spontaneous - chemically induced
Adult
Autoimmune diseases
Female
Humans
Immunologic Factors - adverse effects
Neuromyelitis Optica - drug therapy
Neuromyelitis Optica - immunology
Obstetric Labor Complications - chemically induced
Pre-Eclampsia - chemically induced
Pregnancy
Title Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations
URI https://www.ncbi.nlm.nih.gov/pubmed/32080393
https://www.proquest.com/docview/2370455911
https://www.proquest.com/docview/2476776295
https://www.proquest.com/docview/2371145758
Volume 16
WOSCitedRecordID wos000517918500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwED5BixAL70ehVEZitUrixIlZEKBWDLQqCFC3Kn6EqWloKFL_PefELQzAwhIpcWQn57Pv8539HcC5jBM0HOaC6tCkNOBeQkWUSur5-ECkPo9LOoaX-6jfj4dDMXAOt8Jtq1zMieVErSfK-sjbPosQfYQ4Nq_yN2qzRtnoqkuhsQp1mzbb6nk0XC640JhW566iUNAAgfEiqsnidoGGC7GlXTxZ9kI6_x1hlpamu_Xfb9yGTYcxyXWlFDuwYrJdWO-5KPoePJSMHOO5sVvfCjLJrT-blGcup7Mx0Y6QsyBJpkk-Na-WlGN-Sb6d1SLKJfqsHH778NztPN3eUZdagaqQB--UJzECC09z5aFx0iJFoKeEZlL6QeJphIGCyxT_RGotJUcIrtGSS3yFp16CEOAAatkkM0dADAsE9rdW3FKVYRWJiZVgTCEyCo2XNqC5ENbIjY9i9CWpn4uDCNvkvggbcLYsRsW30YwkM5NZWQWu5RBtxg04rPprlFcMHSPmIxBmgh3_3fYJbPiVBtALrwk1FLI5hTX1gcKftkpdKq9xC-o3nf7gEe_6g94nGFDV7Q
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3JTsQwDLXYBFzYl2ENEhwjaNKmDRJCiEUghhFIgOZWmqWc6AxTFs1P8Y04XYADcOPAtakSJXbs5yR-BthUUYKOw-5QE9iU-sJLqAxTRT2GH2TKRFTQMdw2w1Yrarfl5QC81bkw7lllbRMLQ2062p2RbzMeIvoIcG_udx-pqxrlblfrEhqlWpzb_iuGbPne2RHKd4uxk-Prw1NaVRWgOhD-ExVJhD7VM0J7aJeNTBHjaGm4UsxPPIMISAqV4kDKGKUEok-DTkzhLyL1EvR-2O8gDKMdD12wF7Y_Ajx03mWeVxhI6iMQr29RebSdo6NELOuCNceWSPs_I9rCs51M_rc1mYKJCkOTg1Lpp2HAZjMwelG9EpiFq4Jx5KFv3dO-nHS67ryeFDmlvecHYirC0ZwkmSHdnr13pCP9XfIlF43oqpBpeaA5Bzd_MqF5GMo6mV0EYrkvUZ-NFo6KDbtIbKQl5xqRX2C9tAErtXDiav_n8adkvm_2QxxTMBk0YOOjGTe2u61JMtt5LrrAWBXRdNSAhVI_4m7JQBJzhkCfS770-9jrMHZ6fdGMm2et82UYZ6X20R1vBYZwwe0qjOgXFERvrdBjAnd_rSTvcQEvGQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LT-MwEB5BQYjLLm-6y8NIcLTa2IkTr7Ra8apAQFUQIG4hfoQTaWkWUP8av45xHsABuHHgGke2khnP9409D4BNFSUIHLZNTWBT6gsvoTJMFfUYPpApE1FRjuHyOOx2o6sr2RuDpzoXxoVV1jaxMNSmr90ZeYvxENlHgHuzlVZhEb29zr_BHXUdpNxNa91Oo1SRIzt6RPct_3u4h7LeYqyzf757QKsOA1QHwv9PRRIhvnpGaA9ttJEp8h0tDVeK-YlnkA1JoVJcVBmjlEAmahDQFL4iUi9BJMR5x2EiRJLhN2BiZ7_bO6txAKG8zPoKA0l9pOX1nSqPWjnCJjJb57q52ol09DG_LXCu8_M7_6EZ-FGxa7JdbodZGLPZHEydVPED83Ba1CK5HVkX9JeT_sCd5JMi23R4f0tMVYo0J0lmyGBob1w5ktEf8iZLjeiqxWl51LkAF1_yQYvQyPqZXQZiuS9R040WrkgbTpHYSEvONXLCwHppE1ZqQcWVZcjjVym9P-yHuKZgMmjCxsswbnl3j5Nktn9fTIFeLPLsqAlLpa7Eg7I2ScwZugBc8l-fr70OU6gb8fFh9-g3TLNSEWnbW4EG_m-7CpP6AeUwXKuUmsD1V2vJMxGGOTk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuromyelitis+optica+spectrum+disorders+and+pregnancy%3A+therapeutic+considerations&rft.jtitle=Nature+reviews.+Neurology&rft.au=Mao-Draayer%2C+Yang&rft.au=Thiel%2C+Sandra&rft.au=Mills%2C+Elizabeth+A&rft.au=Chitnis+Tanuja&rft.date=2020-03-01&rft.pub=Nature+Publishing+Group&rft.issn=1759-4758&rft.eissn=1759-4766&rft.volume=16&rft.issue=3&rft.spage=154&rft.epage=170&rft_id=info:doi/10.1038%2Fs41582-020-0313-y&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-4758&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-4758&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-4758&client=summon